Pharmaceutical stocks saw sharp correction today, the Nifty Pharma index dropped around 3% as the investors were shaken by the fear of possible US tariffs. The sell-off affected both big-cap and mid-cap pharma names, reflecting deep unease around export dependency and future earnings visibility.
The weakness comes after the media reports that US administration might impose 100% tariffs on imported pharmaceuticals especially those companies that have failed to enter into a domestic production or pricing bargain in the US.
These agreement require drugmakers to reduce their prices in the US and in few cases commit to increasing manufacturing. Those companies who concur might have temporary tariff relief and those who do not would be subjected to high import charges.
This would be significant issue for the Indian pharmaceutical companies who get 30%-50% of their total revenue from US markets, and therefore are sensitive to any regulatory or cost related interruptions.
The proposed tariff would have a substantial effect on landed costs and disrupt pricing structures in one of their most profitable geographies.
Sun Pharmaceutical fell around 3-4%, and Cipla fell about 3%. Apollo Hospitals also fell by around 2%, a sign of pressure in both pharma manufacturing and healthcare service sectors.
Other significant declines are Biocon that dipped 4.05%, Torrent Pharmaceuticals declined 3.25%, and Wockhardt backed 3.01%.
Laurus Labs fell 2.34%, Glenmark Pharma and Piramal Pharma fell 2.41% and 2.54%, respectively.
Even the more stable names like Divi Labs, Lupin and Zydus Lifesciences reported losses of between 1% and 2%, indicating intensity of the sell-off.
Such a large tariff would squeeze operating margins by 200-500 basis points, particularly in firms with a high exposure to US generics.
Also, the industry is already grappling with price erosion in US generics, increasing compliance costs, and currency volatility.
The tariff introduction would either compel firms to absorb the increased costs or transfer the same to the consumers either way of which may affect demand and profitability.
Also Read: Stock Market Today: Sensex Falls 1,526 Points, Nifty50 Slips to 22,208
The export-driven growth model of Indian pharma is now questionable. Companies might be compelled to accelerate manufacturing in the US, re-price, or to diversify revenues.
However, such strategic changes would involve a huge capital investment and time, which would affect the growth of earnings in the short term.